Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zosuquidar with Daunorubicin and Cytarabine in AML
NCT00129168Phase 2Completed
- Sponsor
- Kanisa Pharmaceuticals
- Start
- Aug 2005
- Primary completion
- Mar 2008
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of zosuquidar in acute myeloid leukemia (AML), sponsored by Kanisa Pharmaceuticals. Started Aug 2005; status: completed.
02
Drugs
zosuquidar
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00129168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00129168.